ВЕРСИЯ ДЛЯ ОЗНАКОМЛЕНИЯ. Руд ь руслан bbКнига про осознанное назначение препаратов версия для ознакомления
 Скачать 4.09 Mb.
|
|
3 9 33. Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, Poulter N, Sever P. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo- Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018 Sep 29;392(10153):1127-1137. doi: 10.1016/S0140-6736(18)31776-8. Epub 2018 Aug 26. Erratum in: Lancet. 2018 Oct 20;392(10156):1402. PMID: 30158072. 34. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992 Feb 15;304(6824):405-12. doi: 10.1136/bmj.304.6824.405. PMID: 1445513; PMCID: PMC1995577. 35. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006 Jun 6;174(12):1737-42. doi: 10.1503/cmaj.060110. Erratum in: CMAJ. 2007 Mar 27;176(7):976. PMID: 16754904; PMCID: PMC1471831. 36. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998 Jun 17;279(23):1903-7. doi: 10.1001/ jama.279.23.1903. PMID: 9634263. 37. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008 May 20;117(20):2706-15; discussion 2715. doi: 10.1161/CIRCULATIONAHA.107.695007. PMID: 18490538. 38. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10;292(18):2227-36. doi: 10.1001/jama.292.18.2227. PMID: 15536109. 39. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006 Jul;99(7):431-6. doi: 10.1093/qjmed/hcl059. Epub 2006 Jun 9. PMID: 16766516. 40. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. PMID: 11937178. 41. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000 Feb 19;355(9204):637-45. doi: 10.1016/s0140-6736(99)10365-9. PMID: 10696996. 42. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens. 1994 Dec;7(12):1041-4. doi: 10.1093/ajh/7.12.1041. PMID: 7702796. 43. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008 Jan 1;148(1):16-29. doi: 10.7326/0003-4819-148-1-200801010-00189. Epub 2007 Nov 5. PMID: 17984484. 44. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens. 1998 Apr;11(4 Pt 1):445-53. doi: 10.1016/s0895-7061(97)00491-3. Erratum in: Am J Hypertens 1998 Jun;11(6 Pt 1):736. PMID: 9607383. 45. Mallion J, Siche J, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999 Oct;13(10):657-64. doi: 10.1038/sj.jhh.1000925. PMID: 10516734. 46. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998 Jan;7(1):53-9. doi: 10.1080/080370598437574. PMID: 9551878. 47. Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, Sullivan J, Oddou-Stock P. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999 Apr;12(4 Pt 1):414-7. doi: 10.1016/s0895-7061(99)00082-5. PMID: 10232502. 48. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 1995 Nov;13(11):1343-51. doi: 10.1097/00004872-199511000-00017. PMID: 8984133. 49. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008 Jan 1;148(1):16-29. doi: 10.7326/0003-4819-148-1-200801010-00189. Epub 2007 Nov 5. PMID: 17984484. 50. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. PMID: 18378520. 51. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007 Mar 20;49(11):1157-63. doi: 10.1016/j.jacc.2006.11.032. PMID: 17367658. 52. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007 Jan;20(1):11-20. doi: 10.1016/j.amjhyper.2006.06.003. PMID: 17198906. 53. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 Jan;25(1):217-26. doi: 10.1097/HJH.0b013e3280103a6b. PMID: 17143194. 54. Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med. 2008 Apr;121(4):265-71. doi: 10.1016/ j.amjmed.2007.11.016. PMID: 18374681; PMCID: PMC2405917. 55. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007 Jul 21;370(9583):221-229. doi: 10.1016/S0140-6736(07)61124-6. Erratum in: Lancet. 2007 Nov 3;370(9598):1542. PMID: 17658393. 56. Rajagopalan S, Bakris GL, Abraham WT, Pitt B, Brook RD. Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension. 2013 Sep;62(3):444-9. doi: 10.1161/HYPERTENSIONAHA.113.01504. Epub 2013 Jul 22. PMID: 23876474. 57. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000 Apr 19;283(15):1967-75. Erratum in: JAMA 2002 Dec 18;288(23):2976. PMID: 10789664. 4 0 |